Literature DB >> 18640578

Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options.

Alexander Dew1, Demetria Collins, Andrew Artz, Elizabeth Rich, Wendy Stock, Kate Swanson, Koen van Besien.   

Abstract

Identification of an HLA identical donor/recipient pair using high-resolution techniques at HLA A, B, C, and DRB1 optimizes survival after adult unrelated hematopoietic stem cell transplant. It has been estimated that roughly 50% of African-Americans have suitable unrelated donors based on serologic typing, but there is little information on the likelihood of identifying an HLA-identical unrelated donor using molecular techniques. From February 2002 to May 2007, we performed 51 unrelated donor searches for African-American patients using the National Marrow Donor Program and found HLA identical unrelated donors for only 3. By contrast, 50 (98%) had at least 1, and often multiple, appropriately matched cord blood units available. Very few African-American recipients have HLA-identical unrelated donors. To allow more African-American patients to proceed to transplant, innovative donor strategies, including adult cord blood transplantation, haploidentical transplant, or the identification of permissive mismatches should be investigated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640578      PMCID: PMC2556036          DOI: 10.1016/j.bbmt.2008.06.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  17 in total

1.  National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants.

Authors:  Carolyn Katovich Hurley; Lee Ann Baxter Lowe; Brent Logan; Chatchada Karanes; Claudio Anasetti; Daniel Weisdorf; Dennis L Confer
Journal:  Biol Blood Marrow Transplant       Date:  2003-10       Impact factor: 5.742

Review 2.  Advances in HLA: practical implications for selecting adult donors and cord blood units.

Authors:  Carolyn Katovich Hurley; John E Wagner; Michelle I Setterholm; Dennis L Confer
Journal:  Biol Blood Marrow Transplant       Date:  2006-01       Impact factor: 5.742

3.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.

Authors:  Vanderson Rocha; Myriam Labopin; Guillermo Sanz; William Arcese; Rainer Schwerdtfeger; Alberto Bosi; Niels Jacobsen; Tapani Ruutu; Marcos de Lima; Jürgen Finke; Francesco Frassoni; Eliane Gluckman
Journal:  N Engl J Med       Date:  2004-11-25       Impact factor: 91.245

4.  Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor.

Authors:  Elena Magro; Carmen Regidor; Rafael Cabrera; Isabel Sanjuán; Rafael Forès; Josè A Garcia-Marco; Elena Ruiz; Santiago Gil; Guiomar Bautista; Isabel Millán; Alejandro Madrigal; Manuel N Fernandez
Journal:  Haematologica       Date:  2006-05       Impact factor: 9.941

5.  Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Richard Aplenc; Todd A Alonzo; Robert B Gerbing; Franklin O Smith; Soheil Meshinchi; Julie A Ross; John Perentesis; William G Woods; Beverly J Lange; Stella M Davies
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

6.  HLA class II and TNF genes in African Americans from the Southeastern United States: regional differences in allele frequencies.

Authors:  Tamara Kuffner; William Whitworth; Maya Jairam; Janet McNicholl
Journal:  Hum Immunol       Date:  2003-06       Impact factor: 2.850

7.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.

Authors:  F Aversa; A Tabilio; A Velardi; I Cunningham; A Terenzi; F Falzetti; L Ruggeri; G Barbabietola; C Aristei; P Latini; Y Reisner; M F Martelli
Journal:  N Engl J Med       Date:  1998-10-22       Impact factor: 91.245

8.  Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.

Authors:  Wolfgang A Bethge; Christoph Faul; Martin Bornhäuser; Gernot Stuhler; Dietrich W Beelen; Peter Lang; Matthias Stelljes; Wichard Vogel; Matthias Hägele; Rupert Handgretinger; Lothar Kanz
Journal:  Blood Cells Mol Dis       Date:  2007-09-14       Impact factor: 3.039

9.  Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow.

Authors:  Juliet N Barker; Timothy P Krepski; Todd E DeFor; Stella M Davies; John E Wagner; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

10.  Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor.

Authors:  P G Beatty; M Mori; E Milford
Journal:  Transplantation       Date:  1995-10-27       Impact factor: 4.939

View more
  23 in total

Review 1.  Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.

Authors:  Koen van Besien
Journal:  Curr Opin Oncol       Date:  2011-11       Impact factor: 3.645

2.  Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study.

Authors:  J Chen; R-X Wang; F Chen; A-N Sun; H-Y Qiu; Z-M Jin; X-W Tang; Y Han; Z-Z Fu; G-S He; M Miao; X Ma; D-P Wu
Journal:  Bone Marrow Transplant       Date:  2013-10-21       Impact factor: 5.483

3.  Myeloablative conditioning regimens with combined of haploidentical and cord blood transplantation for myelodysplastic syndrome patients.

Authors:  P Ke; X-B Bao; X-H Hu; J Zhuang; X-J Wu; Y-J Liu; X-F He; D-P Wu; S-L Xue; X Ma
Journal:  Bone Marrow Transplant       Date:  2017-10-30       Impact factor: 5.483

4.  Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant.

Authors:  Scott R Solomon; Andrew St Martin; Mei-Jie Zhang; Karen Ballen; Asad Bashey; Minoo Battiwalla; Lee Ann Baxter-Lowe; Claudio Brunstein; Saurabh Chhabra; Miguel Angel Diaz Perez; Ephraim J Fuchs; Siddhartha Ganguly; Nancy Hardy; Peiman Hematti; Joseph McGuirk; Edward Peres; Olle Ringden; David Rizzieri; Rizwan Romee; Melhem Solh; David Szwajcer; Marjolein van der Poel; Edmund Waller; Basem M William; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-07       Impact factor: 5.742

5.  Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.

Authors:  Bronwen E Shaw
Journal:  Blood Adv       Date:  2017-02-14

Review 6.  Stem cell transplantation for indolent lymphoma: a reappraisal.

Authors:  Koen van Besien
Journal:  Blood Rev       Date:  2011-09       Impact factor: 8.250

Review 7.  The role of adenosine signaling in sickle cell therapeutics.

Authors:  Joshua J Field; David G Nathan; Joel Linden
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

8.  Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Authors:  Johnnie J Orozco; Aimee Kenoyer; Ethan R Balkin; Ted A Gooley; Donald K Hamlin; D Scott Wilbur; Mark D Hylarides; Sofia H L Frost; Raya Mawad; Paul O'Donnell; Brenda M Sandmaier; Ephraim J Fuchs; Leo Luznik; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel
Journal:  Blood       Date:  2015-11-17       Impact factor: 22.113

9.  Targeting T Cell Bioenergetics by Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells To Prevent Graft-versus-Host Disease.

Authors:  Zachariah A McIver; Jason M Grayson; Benjamin N Coe; Jacqueline E Hill; Gregory A Schamerhorn; Tymish Y Ohulchanskyy; Michelle K Linder; Kellie S Davies; Roy S Weiner; Michael R Detty
Journal:  J Immunol       Date:  2016-07-25       Impact factor: 5.422

10.  Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies.

Authors:  Douglas E Gladstone; Andrea A Zachary; Ephraim J Fuchs; Leo Luznik; Yvette L Kasamon; Karen E King; Robert A Brodsky; Richard J Jones; Mary S Leffell
Journal:  Biol Blood Marrow Transplant       Date:  2013-01-22       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.